After December trial fail, BridgeBio has good news from PhII for LGMD2i drug
BridgeBio Pharma was in need of some good news. It got some from its Phase II trial of a drug for limb-girdle muscular dystrophy type 2i, and will now talk to drug regulators to talk about potential paths to approval.
The biopharma is presenting the results at this week’s Muscular Dystrophy Association Annual Meeting in Nashville. BridgeBio believes that the results show that BBP-418, also known as ribitol, can increase glycosylation of αDG and drive functional improvements and reduce CK, which is a key marker of muscle breakdown. It’s big news for a disease in which there are no approved treatment options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.